From: Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
cGAS-STING agonist | Cancer type | Agent delivery | Ref. |
---|---|---|---|
3′3′-cGAMP | Mouse B cell malignancies | Intraperitoneal injection | [109] |
2′3′-cGAMP | Mouse lymphoma | Intratumoral injection | [63] |
ML RR-S2 CDG | Mouse melanoma | Intratumoral injection | [69] |
ML RR-S2 cGAMP | Mouse melanoma | Intratumoral injection | [69] |
ML RR-S2 CDA (ADU-S100) | Mouse melanoma, colon cancer, mammary carcinoma | Intratumoral injection | |
DMXAA†| Mouse lung cancer, mesothelioma, human lung cancer, and prostate cancer | Intravenous injection | |
Cyclic di-GMP | Mouse melanoma, prostate cancer, glioma, breast cancer | Intratumoral injection | |
DiABZI | Mouse colon tumor | Intravenous injection | [72] |